In response to emerging COVID-19 sub-strains, GENEWIZ has developed workflows specifically tailored for their identification. Mutations within the genome of sub-strains may result in differences in infectability, severity, and vaccine response, therefore characterizing and tracking them is essential for successful surveillance and prevention.
With our global presence, state-of-the-art facilities, and highly-qualified scientific team, we are well-equipped to support the scale and speed needed for your COVID-19 sequencing and surveillance initiatives.
877-GENEWIZ (436-3949), Ext. 1 | CLIA@genewiz.com